Takeda Pharmaceutical Company Limited

Equities

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-05-15 EDT			5-day change	1st Jan Change
5,277.00 ^JPY	+0.40%		+1.23%	+9.14%

05-14	Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million -- Update	DJ
05-14	Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million	DJ

Published on 06/01/2025 at 09:05 pm EDT - Modified on 06/10/2025 at 12:35 pm EDT

S&P Capital IQ

Presenter Speech
Elizabeth Borgeson (Executives)

Welcome to Takeda's ASCO IR event. We'll be discussing the rusfertide Phase III data today. This is Elizabeth from the IR team.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

05-14	Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million -- Update	DJ
05-14	Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million	DJ
05-13	US FDA approves BeOne's drug for a type of blood cancer	RE
05-13	Takeda Pharmaceutical Company Limited, 2026 Earnings Call, May 13, 2026
05-13	Takeda Pharmaceutical's Profit Soars 78% in Fiscal Year 2025	MT
05-13	Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit	DJ
05-13	Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook	MT
05-13	Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year Fiscal Year 2026	CI
05-13	Takeda Pharmaceutical Company Limited Proposes Annual Dividend for Fiscal Year 2025	CI
05-13	Locked in a stalemate with Iran, Trump heads to China	RE
05-13	MORNING BID EUROPE-Locked in a stalemate with Iran, Trump heads to China	RE
05-12	Takeda Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended March 31, 2026	CI
05-11	Weekly Earnings Calendar
05-05	British Columbia reimburses Revestive® (teduglutide for injection) for the treatment of short bowel syndrome	RE
05-04	Takeda Says Phase 2/3 Trial of TAK-881 Meets Endpoint in Primary Immunodeficiency Disease	MT